Nektar Therapeutics Stock Forum

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO).
Rezpegal...

$Nektar Therapeutics (NKTR.US)$ Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes
Benzinga· 1 min ago
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated ...

$Nektar Therapeutics (NKTR.US)$ m
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Nektar Therapeutics (NKTR) published peer-reviewed data from two Phase 1b studies in Nature Communications showing promising results for rezpegaldesleukin in treating atopic dermatitis (AD) and psoriasis (PsO). The studies demonstrated that the drug safely increased regulatory T cells (Tregs) and improved disease outcom...

$Nektar Therapeutics (NKTR.US)$ Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia
Benzinga· 5 mins ago
– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) –
– Eight of nine patients achieved complete remission, all without detectable MRD –

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
Nektar Therapeutics announced multiple presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology Congress.
New proteomic analyses show that REZPEG increases immune-regulating pathways while reducing specific serum proteins elevated in atopic dermatitis patients. REZPEG is a novel regulatory T cell stimulatordesigned to address ...

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...